VitaSpring Biomedical Co. Ltd
VitaSpring Biomedical Co. Ltd., a development-stage biomedical company, engages in the research, development, and commercialization of wellness and healthy lifestyle products. The company focuses on the development of cell-based medical technologies for use in regenerative medicine, preventive health care, beauty, and anti-aging applications. It is also involved in the development of cell medicin… Read more
VitaSpring Biomedical Co. Ltd (VSBC) - Total Liabilities
Latest total liabilities as of October 2022: $761.79K USD
Based on the latest financial reports, VitaSpring Biomedical Co. Ltd (VSBC) has total liabilities worth $761.79K USD as of October 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
VitaSpring Biomedical Co. Ltd - Total Liabilities Trend (2017–2026)
This chart illustrates how VitaSpring Biomedical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
VitaSpring Biomedical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of VitaSpring Biomedical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DOFRB
IS:DOFRB
|
Turkey | TL1.20 Billion |
|
Bank Artha Graha Internasional
JK:INPC
|
Indonesia | Rp28.83 Trillion |
|
199430
KQ:199430
|
Korea | ₩20.09 Billion |
|
EcoGraf Ltd
F:FMK
|
Germany | €2.76 Million |
|
Saturn Metals Ltd
AU:STN
|
Australia | AU$2.68 Million |
|
Graphisoft Park SE Real Estate Development European Company Limited
F:GUV
|
Germany | €80.34 Million |
|
NISSHIN GROUP HOLDINGS Company Limited
MU:NFU
|
Germany | €68.49 Billion |
|
Magyar Bancorp Inc
NASDAQ:MGYR
|
USA | $923.75 Million |
Liability Composition Analysis (2017–2026)
This chart breaks down VitaSpring Biomedical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how VitaSpring Biomedical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for VitaSpring Biomedical Co. Ltd (2017–2026)
The table below shows the annual total liabilities of VitaSpring Biomedical Co. Ltd from 2017 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-01-31 | $3.16 Million | 0.00% |
| 2023-01-31 | $3.16 Million | +56.05% |
| 2022-01-31 | $2.03 Million | +2078.27% |
| 2021-01-31 | $93.03K | -- |
| 2020-01-31 | $0.00 | -- |
| 2019-01-31 | $18.35K | +12.51% |
| 2018-01-31 | $16.31K | +919.38% |
| 2017-01-31 | $1.60K | -- |